Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications

Chen, Xiewan; Liao, Rongxia; Li, Dezhi; Sun, Jianping

doi:10.18632/oncotarget.14230

Cited by 55 publications

(42 citation statements)

References 96 publications

(130 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 Development of chemotherapy, radiotherapy, and targeted therapy, such as trastuzumab, has decreased mortality of this disease, but millions of breast cancer patients will still die because of failure treatment. One of the well-known explanations for this is the presence of cancer stem-like cell (CSC) which is resistant to chemotherapeutics, 2 radiation, 3 and trastuzumab. 4 In addition to resistance to therapies, CSC is also responsible for tissue invasion, 5 metastasis, and recurrence.…”

Section: Introductionmentioning

confidence: 99%

CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer

Wang¹,

Tu²,

Du³

et al. 2018

OTT

View full text Add to dashboard Cite

BackgroundBreast cancer is the leading cause of mortality from cancer in women worldwide, and cancer stem-like cell (CSC) is responsible for failure treatment of breast cancer. It plays an important role in resistant disease and metastasis. CD44/CD24 and ALDH are well-accepted protein markers of breast CSC, and it was reported that distinct subtypes of breast CSC were identified by the 2 markers. It is possible that there are various kinds of breast CSC which could be identified by different markers, and CSC markers utilized at present are not enough to fully understand breast CSC. Finding out more novel CSC markers is necessary. CXCR2 is involved in breast cancer metastasis, treatment resistance, and recurrence and has positive cross-talk with known breast CSC protein markers. It can be concluded that CXCR2 is related to breast CSC, and further study is in need.ResultsIn this study, we assessed expression of CXCR2 with immunohistochemistry in breast cancer tissues from 37 patients and discovered that level of CXCR2 was significantly lower in triple-negative breast cancer (TNBC) compared with non-TNBC. CXCR2 expression decreased in estrogen receptor-negative or HER2-negative breast cancer, but not progesterone receptor-negative counterparts. By immunofluorescence, we observed high coexpression rate of CXCR2 and CSC-related proteins, including NANOG and SOX2. To prove our speculation that CXCR2 was a novel CSC marker for TNBC, we used 4T1 cell, which is a TNBC cell line, to analyze CXCR2-positive subpopulations and observed that CXCR2-positive 4T1 cells showed characteristics of CSC, including resistance to cisplatinum, radiation, and hypoxia, low proportion (around 1%), much more tumor xenografts, tumor spherule formation, and higher levels of CSC-related mRNA compared with CXCR2-negative cells.ConclusionCXCR2 is an acceptable and newly discovered CSC marker for only TNBC.

show abstract

Section: Introductionmentioning

confidence: 99%

CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer

Wang¹,

Tu²,

Du³

et al. 2018

OTT

View full text Add to dashboard Cite

show abstract

“…Signaling within the tumor microenvironment (tumor niche), including oxygenation, cell-to-cell contact and secreted factors, could induce differentiated tumor cells to re-acquire stem celllike properties (62). Additionally, radio-and chemotherapy treatments have been shown to enrich CSC subpopulations in residual tumors because of selective pressure on drug-resistant cells (65)(66)(67) and due to tumor cell plasticity (64). Even though the CSC state has high plasticity, it is of high clinical importance as a potential marker for clinical outcome and target for anticancer treatment (68,69).…”

Section: The Plasticity Modelmentioning

confidence: 99%

Novel Therapeutic Strategies for Ovarian Cancer Stem Cells

et al. 2020

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the most lethal gynecologic malignancies. Due to the lack of specific symptoms and screening methods, this disease is usually diagnosed only at an advanced and metastatic stage. The gold-standard treatment for OC patients consists of debulking surgery followed by taxane combined with platinum-based chemotherapy. Most patients show complete clinical remission after first-line therapy, but the majority of them ultimately relapse, developing radio-and chemoresistant tumors. It is now proposed that the cause of recurrence and reduced therapy efficacy is the presence of small populations of cancer stem cells (CSCs). These cells are usually resistant against conventional cancer therapies and for this reason, effective targeted therapies for the complete eradication of CSCs are urgently needed. In this review article, we highlight the mechanisms of CSC therapy resistance, epithelial-to-mesenchymal transition, stemness, and novel therapeutic strategies for ovarian CSCs.

show abstract

“…With regard to the role of CSCs in induced drug resistance, studies across human tumors, including NB, widely agreed that CSCs are inherently resistant to radiotherapy and/or chemotherapy [140][141][142][143] . However, the understanding of the acquired genetic alterations in non-stem cancer cells and their transformation into iCSCs after radiochemotherapy is recently on an upsurge (reviewed in detail elsewhere [144] ). ICSCs formation was documented with common chemotherapy drugs [fluorouracil (5-FU), DOX] and with various qualities of radiation.…”

Section: Induced Cscs and Therapy Resistancementioning

confidence: 99%

Cancer stem cells in neuroblastoma therapy resistance

Aravindan¹,

Jain²,

Somasundaram³

et al. 2019

CDR

View full text Add to dashboard Cite

Neuroblastoma (NB) is the most common cancer of infancy and accounts for nearly one tenth of pediatric cancer deaths. This mortality rate has been attributed to the > 50% frequency of relapse despite intensive, multimodal clinical therapy in patients with progressive NB. Given the disease's heterogeneity and developed resistance, attaining a cure after relapse of progressive NB is highly challenging. A rapid decrease in the timeline between successive recurrences is likely due to the ongoing acquisition of genetic rearrangements in undifferentiated NB-cancer stem cells (CSCs). In this review, we present the current understanding of NB-CSCs, their intrinsic role in tumorigenesis, their function in disease progression, and their influence on acquired therapy resistance and tumor evolution. In particular, this review focus on the intrinsic involvement of stem cells and signaling in the genesis of NB, the function of pre-existing CSCs in NB progression and therapy response, the formation and influence of induced CSCs (iCSCs) in drug resistance and tumor evolution, and the development of a CSC-targeted therapeutic approach.

show abstract

Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications

Cited by 55 publications

References 96 publications

CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer

CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer

Novel Therapeutic Strategies for Ovarian Cancer Stem Cells

Cancer stem cells in neuroblastoma therapy resistance

Contact Info

Product

Resources

About